An analysis of the Novavax COVID-19 vaccine using clinical and real-world data found that the benefits outweighed the risk of myocarditis or pericarditis, a team from the company reported in the March 16 edition of Vaccine.

Rare cases of myocarditis and pericarditis have been reported with the Novavax vaccine, similar to those reported with the mRNA vaccines. The adjuvanted protein-based vaccine, which is made on a more traditional platform, entered the US market in the fall of 2023 and has been authorized for emergency use in a two-dose series or as a booster in 45 countries.